Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

4.3K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.3K
Agonism and Antagonism: Quantification01:14

Agonism and Antagonism: Quantification

1.4K
When drugs are administered, they can elicit either an agonist or antagonist effect on the body. Agonism occurs when a drug activates a specific receptor, triggering a biological response. On the other hand, antagonism happens when a drug binds to the same receptors but blocks their activation, thereby preventing a biological response.
To quantify these effects, researchers use a dose-response curve, which provides valuable information about the potency and efficacy of a drug. Potency refers to...
1.4K
The Two-State Receptor Model01:29

The Two-State Receptor Model

3.5K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
3.5K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

4.9K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
4.9K
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

11.6K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
11.6K
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

8.3K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
8.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Small-molecule modulation of β-arrestins.

Nature·2026
Same author

Application of large language models in clinical decision-making for dry eye disease.

BMC medical informatics and decision making·2026
Same author

A conserved hydrophobic interaction governs GPCR-transducer association.

bioRxiv : the preprint server for biology·2026
Same author

Skeletal muscle as an endocrine and paracrine organ in breast cancer biology: a narrative review.

Discover oncology·2026
Same author

Intra-tumoral lymphocyte scoring in colorectal cancer: improving prognostic utility and correlation with underlying cancer biology.

Frontiers in gastroenterology (Lausanne, Switzerland)·2026
Same author

Healthy Dietary Patterns and Risk of Major Eye Diseases: Evidence From Nationally Population-Based Data and Bibliometric Analysis.

Food science & nutrition·2026

Related Experiment Video

Updated: May 1, 2026

Quantifying Agonist Activity at G Protein-coupled Receptors
11:45

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

18.5K

Recent developments in biased agonism.

James W Wisler1, Kunhong Xiao1, Alex R B Thomsen1

  • 1Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.

Current Opinion in Cell Biology
|April 1, 2014
PubMed
Summary
This summary is machine-generated.

Ligands can now be designed to activate G protein-coupled receptors (GPCRs) into specific conformations, enabling targeted downstream signaling. This biased agonism offers new therapeutic strategies for various diseases.

More Related Videos

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

8.4K
Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
09:39

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications

Published on: January 27, 2014

11.8K

Related Experiment Videos

Last Updated: May 1, 2026

Quantifying Agonist Activity at G Protein-coupled Receptors
11:45

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

18.5K
A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

8.4K
Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
09:39

Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications

Published on: January 27, 2014

11.8K

Area of Science:

  • Pharmacology
  • Biochemistry
  • Molecular Biology

Background:

  • The traditional view of G protein-coupled receptor (GPCR) activation involves a single 'active' conformation.
  • Recent research reveals that ligands can induce distinct GPCR active states with varied signaling outcomes.

Purpose of the Study:

  • To review recent advancements in understanding biased agonism at GPCRs.
  • To highlight developments in structural, biophysical, and clinical aspects of biased ligands.

Main Methods:

  • Literature review of recent studies on GPCR biased agonism.
  • Analysis of structural and biophysical data related to ligand-induced receptor conformations.
  • Examination of methods for quantifying ligand efficacy and clinical applications.

Main Results:

  • Significant progress has been made in elucidating the mechanisms of biased agonism.
  • Improved techniques for characterizing and quantifying ligand efficacy have emerged.
  • Clinical development of novel biased ligands is advancing.

Conclusions:

  • Biased agonism represents a paradigm shift in GPCR drug discovery.
  • Targeting distinct receptor conformations offers potential for more selective and effective therapeutics.
  • Continued research in this area promises novel treatment options.